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Increased expression of the homologue of
enhancer-of-split 1 protects neurons from beta
amyloid neurotoxicity and hints at an alternative
role for transforming growth factor beta1 as a
neuroprotector
Pedro J Chacón* and Alfredo Rodríguez-Tébar
Abstract
Introduction: Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the deposition of
b-amyloid (Ab) in the brain, which produces progressive neuronal loss and dementia. We recently demonstrated
that the noxious effects of Ab on cultured hippocampal neurons are in part provoked by the antagonism of nerve
growth factor (NGF) signalling, which impairs the activation of nuclear factor B (NF-B) by impeding the tyrosine
phosphorylation of I-Ba. As a result, the expression of the homologue of Enhancer-of split 1 (Hes1) gene is
downregulated and ultimately, gamma-aminobutyric acid (GABA)-ergic connectivity is lost.
Methods: Hes1 activity was promoted in cultured hippocampal neurons by overexpressing a Hes1-encoding
plasmid or by upregulating this gene by activating NF-B through different approaches (overexpressing either the
I-B kinaseb, or p65/RelA/NF-B). Alternatively neurons were exposed to TGFb1. Dendrite patterning, GABAergic
connectivity and cell survival were analyzed by immunofluorescence microscopy. Hes1 expression was determined
by real-time PCR. NF-B activation was measured using the dual-luciferase reporter assay.
Results: The expression of Hes1 abolished the effects of Ab on dendritic patterning and GABAergic input, and it
prevented the death of the cultured neurons. TGFb1, a known neuroprotector, could counteract the deleterious
effects of Ab by inducing NF-B activation following the serine phosphorylation of I-Ba. Indeed, the number of
GABAergic terminals generated by inducing Hes1 expression was doubled.
Conclusion: Our data define some of the mechanisms involved in Ab-mediated cell death and they point to
potential means to counteract this noxious activity.
Introduction
The amyloid hypothesis considers amyloid beta (Ab) as
the principal agent underlying the various manifestations
of Alzheimer’s disease (AD). Accordingly, most therapeu-
tic approaches for AD treatment target the Ab peptide,
which induces the formation of amyloid deposits in the
brain [1]. These strategies attempt to limit Ab production
and fibril formation, or to increase Ab clearance from
brain deposits. This latter approach has been the focus of
much investigation, with active and passive methods to
immunize against Ab effectively reducing brain Ab con-
tent. However, this reduction in amyloid content has not
been conclusively associated with improvements in cog-
nitive performance or a slowing in the progression of AD
[2,3].
An alternative approach to AD therapy involves inter-
fering with the signals transduced by Ab to offset neuro-
nal deterioration and death. While neuronal Ab signaling
pathways have been studied extensively, many of the
underlying mechanisms remain elusive. Several studies
have related Ab neurotoxicity with NGF neurotrophy
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and indeed, some current therapeutic approaches for AD
involve the use of NGF or other compounds that mimic
its effects [4-9]. The cellular and molecular bases under-
lying the antagonism of NGF by Ab have been described
recently, at least in part. Accordingly, Ab competes with
nerve growth factor (NGF) binding to p75NTR [10,11],
thereby preventing the activation of NF-B by impairing
the tyrosine phosphorylation and the subsequent degra-
dation of I-Ba [12]. The inhibition of nuclear factor
kappa-B (NF-B) mediated by Ab results in the downre-
gulation of the enhancer of split homolog 1 (Hes1) gene,
which is known to influence dendrite patterning and
gamma-aminobutyric acid (GABA)-ergic inputs [13,14].
We recently reported that Ab impairs the initial steps
of NGF signalling at the level of RhoA GTPase and pro-
tein tyrosine phosphatase 1B (PTP1B) [15]. Furthermore,
we demonstrated that potentiation of NGF signalling (for
example, by inhibiting RhoA GTPase and activating
PTP1B) confers neuronal resistance to Ab neurotoxicity.
In the present study, we explored alternative means of
activating NF-B and promoting Hes1 expression. We
found that overexpression of I-b kinase (IKKb) a kinase
that phosphorylates I-Ba (an NF-B inhibitor), p65/
RelA or Hes1 abolished the effects of Ab on dendritic
patterning, GABAergic input and the survival of cultured
hippocampal neurons. Furthermore, administration of
transforming growth factor b1 (TGFb1) produced similar
effects, augmenting Hes1 expression and GABAergic
input, and conferring resistance to Ab toxicity. These
results further our understanding of Ab toxicity in AD
and they open new perspectives for AD treatment using
anti-amyloid approaches.
Materials and methods
Antibodies
The following primary antibodies were used for immuno-
cytochemistry: rabbit anti-enhanced green fluorescent
protein (EGFP, 1:500: Invitrogen, Carlsbad, CA, USA),
chicken anti-EGFP (1:500: Chemicon, Hampshire,
UK), mouse anti-Myc (1:400: Roche Applied Science,
Mannheim, Germany), mouse anti-FLAG (1:500: Sigma-
Aldrich, Madrid, Spain) and rabbit anti-vesicular inhibitory
amino acid transporter (VIAAT, 1:400: Chemicon). The
following secondary antibodies were used: goat anti-rabbit
Cy2 (1:1000), goat anti-mouse Cy3 (1:1000), goat anti-rabbit
Cy3 (1:1000) and goat-anti mouse Cy5 (1:500: all from
Jackson Immuno Research, West Grove, USA), and goat
anti-chicken Alexa-fluor 488 (1:1000: Invitrogen).
Amyloid b preparation and characterization
Amyloid b (1-42) was purchased from NeoMPS (Stras-
bourg, France) and to obtain oligomeric forms, the peptide
was dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol and the
solution was allowed to evaporate for 2 h at room
temperature. The peptide film was dissolved in dimethyl
sulfoxide (DMSO), sonicated in a water bath for 10 min-
utes and diluted to 100 μM in PBS. This solution was then
briefly vortexed and incubated overnight at 4°C. Aliquots
were stored at -20°C. Our Ab preparations were resolved
by 12% Bis-Tris gel electrophoresis and electrotransferred
to polyvinylidene difluoride (PVDF) membranes, which
were probed with a mouse monoclonal anti-b Amyloid
antibody (clone BAM-10, diluted 1:2,000: Sigma Aldrich).
After further incubation with an horseradish peroxidise
(HRP)-conjugated anti-mouse antibody (1:10,000: Jackson
Immuno Research, West Grove, USA), immunoreactive
Ab species were visualised by chemiluminiscence. This
analysis revealed that most Ab forms were monomeric
and dimeric with a less prominent trimeric and tetrameric
component (Figure S1A in Additional file 1). To kill neu-
rons in culture, a concentration of 5 μM was established
empirically (Figure S1B in Additional file 1).
Other chemicals
Recombinant TGFb1 was purchased from Preprotech EC
LTD (London, UK). The cell-permeable NF-B inhibitor
peptide SN-50 and its inactive control, SN-50M, were
obtained from Calbiochem (Darmstadt, Germany).
Expression vectors for neuronal transfection
EGFP-expressing vector (pEGFP-N1) was obtained from
Biosciences/Clontech (Palo Alto, CA, USA). Vectors
expressing the wild type (wt) forms of IKKa (pCDNA-
HA-IKKa) and IKKb (pRK5cFLAG-IKKb) were kindly
provided by Lisardo Boscá [16]. Vectors encoding mutant
forms of I-Ba (3XFLAG-pCMV-I-BaS32/36A and
3XFLAG-pCMV-I-BaY42F) were described previously
[17]. A FLAG-tagged vector encoding p65/RelA (pCMV-
Tag1-p65) was kindly provided by Mayte Coiras [18]. Vec-
tors encoding Hes1 (pCLIG-Hes1) and Hes6 (pIRES-Hes6)
were kindly provided by Ryoichiro Kageyama [19] and Phil
Jones [20], respectively. Myc-tagged forms of Hes1 and
Hes6 were obtained by inserting the corresponding cDNA
encoding sequence from previous vectors into the NcoI/
EcoRI and NcoI/StuI sites of the pCS2+MT vector.
Cell culture
Primary hippocampal neuronal cultures were prepared as
described previously [21], with some modifications. Briefly,
hippocampi were dissected from embryonic day 17 (E17)
CD1 mouse foetuses and dissociated into single cells fol-
lowing trypsin digestion (Worthington, Lakewood, USA)
and DNase I treatment (Roche Applied Science). Neurons
were plated on glass coverslips or in plastic dishes coated
with poly-L-lysine (Sigma-Aldrich, Madrid, Spain), and
then cultured in Neurobasal A supplemented with 2 mM
GlutaMAX I, 100 units/mL penicillin and 100 μg/mL
streptomycin (Gibco BRL, Crewe, UK). After 7 days
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in vitro (DIV) the neurons were exposed to either TGFb1
or Ab.
Neuronal transfection
For fluorescence immunocytochemistry, cultured neurons
(7 days in vitro, DIV) were transfected with different vec-
tors using the Effectene Transfection Reagent (Qiagen
GmbH, Hilden, Germany) according to the manufacturer’s
instructions, with some modifications. Briefly, 0.6 μg of
DNA was added to 120 μl of EC buffer and 3.5 μL of
enhancer, and then left for 5 minutes at room temperature
before 10 μL of Effectene was added. After 15 minutes
incubation at room temperature, the final solution was
added to a 35 mm cell culture dish containing hippocam-
pal neurons, for 3 h before the medium was changed. Less
than 0.5% of the neurons were transfected in each dish,
permitting the morphology of the neurons to be analyzed
without the interference of neighboring labeled neurons.
To determine Hes1 mRNA, 300,000 neurons were trans-
fected with different vectors using Lipofectamine LTX
(Invitrogen), following the protocol recommended by the
manufacturer. The rate of transfection was 20-25% of the
total number of cells.
Immunocytochemistry, image acquisition and
morphometric analysis of labeled hippocampal neurons
Neurons were fixed for 30 minutes in 4% paraformalde-
hyde (PFA) in PBS 18 h after transfection, permeabilized
for 15 minutes at room temperature with 0.5% Triton
X-100 in PBS and blocked with 10% goat serum in PBS
containing 0.1% Triton X-100. The neurons were then
incubated with the primary and secondary antibodies. To
verify that the labeling was caused specifically by the pri-
mary antibodies, it was either omitted or replaced by simi-
larly diluted normal serum from the same species.
Our methods for the evaluation of dendritic morphology
and presynaptic terminal identification in dissociated cell
cultures have been described previously [14]. Briefly,
labeled neurons were visualized by standard epifluores-
cence under a Plan-Neofluar 63× oil objective with a
numerical aperture of 1.3 (Zeiss, Oberkochen, Germany).
Terminal counts and analysis of dendrite morphology
were performed manually. A circular region of interest
(ROI) with a diameter of 50 μm was projected onto the
EGFP-labeled neuron, its centre roughly coinciding with
the centre of the soma. The dendrite length was expressed
as the number of dendritic trees that exceeded the limit of
the ROI (number of dendrites > 50 μm). In co-transfection
experiments, only double-labeled cells were analysed,
representing > 90% of the single-labeled cells. Synaptic
terminals in contact with an EGFP-labeled neuron were
identified by single immunofluorescence, when an anti-
body against VIAAT was used.
Cell survival
After treatment, neurons were fixed for 30 minutes in
4% paraformaldehyde (PFA) in PBS and the nuclei were
immunostained with the fluorescent dye 4’,6-diamidino-
2-phenylindole (DAPI: Sigma-Aldrich). Non-viable neu-
rons were recognized by nuclear condensation and/or
fragmented chromatin. In two independent experiments,
the number of viable neurons was counted in triplicate
in approximately 50 fields. In co-transfection experi-
ments, only the nuclei of double-labeled cells were
analysed.
Quantitative real time polymerase chain reaction (PCR)
After treatments, total RNA was extracted from cultures at
7 DIV using the Illustra RNAspin Mini kit (GE-Health-
care, Piscataway, NJ, USA) and first strand cDNA was pre-
pared from the RNA using the First Strand Synthesis kit
according to the manufacturer’s instructions (Fermentas
GmbH, St Leon-Rot, Germany). Quantitative PCR was
performed using the ABI Prism 7000 Sequence Detector
(Applied Biosystems, Weiterstadt, Germany). TaqMan
probes and primers for Hes1 and the housekeeping gene
GADPH (as a control) were selected as the Assay-on-
Demand gene expression products (Applied Biosystems).
All TaqMan probes were labeled with 6-carboxy fluores-
cein (FAM) and real time PCR was performed using the
TaqMan Universal PCR Master Mix according to the
manufacturer’s instructions. Hes1 expression was normal-
ized to GAPDH expression.
Analysis of reporter gene activity
For reporter gene studies, 12-well plates (Becton Dickinson)
containing 200,000 hippocampal neurons were transfected
using the Lipofectamine LTX (Invitrogen) transfection
reagent according to the manufacturer’s instructions.
Transfection efficiency ranged from 20 to 25% in control
experiments, as revealed by co-transfection with pEGFP-
N1 (Biosciences/Clontech). Cells were co-transfected with
0.5 μg/well of a plasmid containing five tandem repeats of
the B enhancer element upstream of the coding sequence
of firefly-luciferase (pNF-B-luc; Clontech), along with
0.1 μg of a plasmid encoding Renilla-luciferase (phRL-TK-
luc: Promega, Madison, WI) as a transfection control for
normalization in dual-luciferase assays. Dual-Luficerase
reporter assays were performed according to the manufac-
turer’s recommendations (Promega).
Statistical analysis
The data are presented as the mean ± standard error of
the mean (SEM). Unpaired Student’s t-tests were used to
determine the significance, denoted as *P < 0.05, **P <
0.01, and ***P < 0.001. All experiments were repeated at
least twice.
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Results
Hes1 in neuronal morphology, connectivity and survival
Earlier studies revealed that Hes1 mediates the effects of
NGF on neuronal morphology and connectivity. NGF
increases both dendrite length and GABAergic connectiv-
ity in cultured hippocampal neurons, effects that are abro-
gated by overexpression of Hes6 [13,14], a natural
inhibitor of Hes1 [19]. We transfected a Hes1-expressing
vector into cultured hippocampal neurons and analyzed
the effects on dendrite morphology and synaptic connec-
tivity. Overexpression of Hes1 increased the length of pri-
mary dendrites while decreasing their number (Figure 1A,
B), and it enhanced GABAergic connectivity, as evident by
immunostaining for VIAAT-positive clusters (Figure 1C).
Interestingly, Hes1 transfection of neurons protected these
cells from the neurotoxic effects of Ab. Indeed, while oli-
gomerization of Ab (Figure S1A in Additional file 1)
decreased the length and increased the number of primary
dendrites, albeit decreasing GABAergic input, these effects
were completely reversed by Hes1 transfection (Figure 1A,
B and 1C). Moreover, Hes1 overexpression attenuated the
effects of Ab on neuronal survival. Using a concentration
of 5 μM Ab(1-42) in these studies to ensure that most
cells would die during the experiment (performed over
90 h (Figure S1B in Additional file 1), prior transfection
with Hes1 rescued 50% of neurons from this Ab-induced
death (Figure 1D). Taken together, these findings demon-
strate that optimal expression of Hes1 counteracts the
effects of Ab on neurons at all the levels examined here.
Activation of NF-B blocks the effects of Ab on neuronal
morphology and connectivity
Having previously revealed that NGF augments Hes1 by
activating NF-B [13], the link between NF-B activation
and Hes1 expression was confirmed here using an alter-
native experimental approach. Cultured hippocampal
neurons were transfected with a plasmid expressing p65/
RelA, and Hes1 expression was assessed by quantitative
PCR. Although only 20 to 25% of neurons were trans-
fected, a significant increase (35 to 40%) in Hes1 mRNA
was evident throughout the culture (Figure 2A). Trans-
fected, myc-tagged p65/RelA was predominantly found
in the nucleus, as expected given its capacity to promote
Hes1 expression (Figure 2B). Moreover, p65/RelA overex-
pression produced marked changes in dendrite arborisa-
tion, increasing the length and decreasing the number of
primary dendrites (Figure 2B). These effects were paral-
leled by a substantial increase in GABAergic connectivity
(Figure 2B, D) concomitant with an increase in Hes1
expression (Figure 1). As seen following Hes1 transfec-
tion, p65/RelA transfection blocked the effects of Ab on
both dendrite morphology and connectivity, preventing
the increase in dendrite length and the decrease in den-
drite number induced by Ab (Figure 2A, B and 2C).
Indeed, p65/RelA overexpression also prevented the
decrease in VIAAT-positive terminals induced by Ab.
The anti-amyloid effects of p65/RelA overexpression on
neuronal survival could not be studied, as p65/RelA over-
expression induced neuronal death two days after trans-
fection (that is, before Ab had noxious effects on
cultured neurons).
IKKb activation counteracts the effects of beta-amyloid
NGF was shown to activate NF-B via tyrosine phosphor-
ylation and the subsequent degradation of I-Ba [12]. The
canonical NF-B activation pathway involves Ser(32,36)
phosphorylation of I-Ba catalysed by the IKKs, and
hence we tested whether increased activity of IKK proteins
conferred amyloid resistance to cultured neurons. When
cultured hippocampal neurons were transfected with a
plasmid overexpressing IKKb, again only 20 to 25% of
neurons were transfected (data not shown). Nonetheless,
the levels of Hes1 mRNA increased significantly (25 to
30%) throughout the entire culture (Figure 3A). As
expected, IKKb overexpression produced similar altera-
tions in neuronal morphology as Hes1 or p65/RelA trans-
fection (longer and fewer dendrites) (Figure 3B). In
addition, IKKb transfection conferred hippocampal neu-
rons with resistance to Ab (Figure 3C, left panel). These
effects were specific to IKKb as transfection with IKKa
produced no noticeable changes in dendrites (not shown)
and conferred only very modest resistance to Ab neuro-
toxicity (Figure 3C, right panel).
Effects of TGFb1 on neuronal morphology, connectivity
and survival
Based on the changes observed in dendrite morphology,
and in neuronal connectivity and survival following Hes1
overexpression, we investigated the effects of an alterna-
tive means of activating NF-B using the cytokine
TGFb1 [22]. The role of TGFb1 in neuronal polarity and
axonal specification has been studied previously [23], and
while TGFb1-3 promote dendrite growth in retinal gang-
lion cells [24], the effects of TGFb on neuronal plasticity
remain unclear. We first studied the effects of TGFb1 on
dendritic patterning in cultured hippocampal neurons
after 7 DIV. Exposure to TGFb1 increased the number of
primary dendrites while decreasing the number of
remaining dendrites (Figure 4A). Moreover, GABAergic
connectivity was augmented in cultured hippocampal
neurons treated with TGFb1, as revealed by VIAAT
immunostaining (Figure 4A, right panel). Varicosities
containing VIAAT also increased upon TGFb1 adminis-
tration. The effects of TGFb1 were mediated by Hes1 as
TGFb1 had no such activity in neurons transfected with
the Hes1 inhibitor Hes6 [19,20,25]. Impairment of Hes1
also prevented TGFb1 from altering dendrite patterning
and GABAergic connectivity.
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Although the TGFb1 transduction pathway that modu-
lates neuronal plasticity is poorly understood (but see
Discussion), TGFb1 is known to activate NF-B in hip-
pocampal neurons [22]. We found that this activation of
NF-B by TGFb1 may be involved in neuronal plasticity,
and thus we analyzed the morphological changes induced
by TGFb1 in cells transfected with either a non-serine
phosphorylatable mutant I-Ba or a non-tyrosine phos-
phorylatable form of I-Ba. Transfection with the serine
mutant blocked the effects of TGFb1 on dendrite elonga-
tion and GABAergic connectivity (Figure 4B), whereas
transfection with the tyrosine mutant of I-Ba had no
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Figure 1 Hes1 overexpression blocked the effects of amyloid beta (Ab) on the morphology, GABAergic connectivity and survival of
cultured hippocampal neurons. (A-C) E17 hippocampal neurons were plated at a density of 40,000 cells/cm2 and cultured for 7 days in vitro
(DIV). Neurons were treated with Ab (5 μM), and/or they were co-transfected with enhanced green fluorescent protein (EGFP) and a myc-tagged
Hes1 vector for 16 h. The cells were fixed and labeled with anti-EGFP, anti-myc and anti- vesicular inhibitory amino acid transporter (VIAAT)
antibodies, and examined by immunofluorescence. (A) Representative micrographs of cultured neurons under different conditions. Nuclear
labeling (in purple) corresponds to myc-tagged Hes1. Punctuated red dots correspond to VIAAT immunostaining. Lower panels show the boxed
regions at higher magnification. (B) Morphometric analysis was performed as indicated in Materials and methods. Note that Ab decreased the
length of primary dendrites (left panel) and increased their number (right panel), whereas Hes1 induced opposite effects, counteracting those of
Ab. (C) Hes1 overexpression increased the number of GABAergic terminals in cultured neurons, overriding the decrease induced by Ab
administration. (D) 7 DIV neurons (30,000 cells/cm2) were treated with Ab (5 μM). Two days later the neurons were co-transfected with EGFP and
the myc-tagged Hes1 vector, and the cells were stained with anti-EGFP, anti-myc antibodies and 4’,6-diamidino-2-phenylindole (DAPI) on the
following day. EGFP and myc dual-labeled cells with intact nuclei were counted. Approximately 50% of transfected neurons survived Ab
treatment. *P < 0.05, **P < 0.01, and ***P < 0.001.
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Figure 2 Transfection of p65/RelA promoted Hes1 expression and counteracted the effects of amyloid beta (Ab) on the morphology
and GABAergic connectivity of cultured hippocampal neurons. (A) 7 days in vitro (DIV) neurons (300,000 cells) were transfected with a
plasmid encoding myc-tagged p65/RelA. After 16 h, the cells were lysed and processed for real time-PCR, showing that Hes1 expression levels
increased by 35%. (B-D) Cultured hippocampal neurons (40,000 cells/cm2, 7 DIV) were co-transfected with enhanced green fluorescent protein
(EGFP) and myc-p65/RelA plasmids, treated with Ab (5 μM) and incubated for a further 16 h, before analyzing dendritic patterning (B, C) and
GABAergic connectivity (B, D). (B) Representative micrographs of 7 DIV hippocampal neurons treated with Ab and/or transfected with p65/RelA.
EGFP immunostaining (green) and the transfected p65/RelA mostly located to the nucleus (purple). Vesicular inhibitory amino acid transporter
(VIAAT) was evident as punctuated red dots. Lower panels show the boxed regions at higher magnification. (C) Morphometric analysis of treated
neurons. p65/RelA overexpression increased the length (left panel) but decreased the number (right panel) of primary dendrites, thereby
counteracting the effects of Ab. (D) p65/RelA overexpression increased the number of GABAergic terminals in cultured neurons and overrode
the decrease in GABAergic terminals produced by Ab. *P < 0.05, **P < 0.01, and ***P < 0.001.
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effect on TGFb1 activity. Accordingly, the effects of
TGFb1 on neuronal plasticity are dependent upon serine
phosphorylation of I-B and its capacity to activate NF-
B. By contrast, overexpression of the tyrosine mutant
form had no effect on TGFb1 activity (Figure 4B). In con-
junction with previous findings [12], these results suggest
Figure 3 I-B kinase (IKK-b) induces Hes1 expression, modulates dendritic morphology and neuronal survival, and it counteracts
amyloid beta (Ab) activity. (A) The efficiency of transfecting 7 days in vitro (DIV) cultured neurons (300,000 cells) with a vector expressing Flag-
tagged IKKb was 20-25%. After 16 h, the cells were lysed and Hes1 expression was quantified by real time PCR, and transfection of IKKb
increased Hes-1 mRNA levels by 35%. (B) Hippocampal neurons were cultured for 7 DIV (40,000 cells/cm2), treated with Ab (5 μM), and/or co-
transfected with enhanced fluorescent green protein (EGFP) and FLAG-tagged IKK-b for 16 h. Transfection with IKKb increased the length (left
panel) but decreased the number (right panel) of primary dendrites, and blocked the effect of Ab on dendrite morphology. (C) 7 DIV
hippocampal neurons (30,000 cells/cm2) were cultured for 7 days and then treated with Ab (5 μM). Two days later, the neurons were co-
transfected with EGFP, FLAG-tagged IKKb and/or HA-tagged IKKa and the number of live cells was determined on the following day. IKKb
transfection rescued about 50% of neurons from Ab-induced death (left panel), whereas this rescue was more modest when neurons were
transfected with IKKa rather than IKKb (right panel). *P < 0.05, **P < 0.01, and ***P < 0.001.
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that Hes1 can be activated by either NGF or TGFb1. Both
these factors activate NF-B, although the former
degrades I-Ba by phosphorylation at tyrosine 42 [12]
and the latter by phosphorylating serines 32 and 36.
Anti-amyloid effects of TGFb1
As Ab prevents NGF-induced tyrosine phosphorylation
and the subsequent degradation of I-Ba [12], we asked
whether TGFb1 could counteract the noxious effects of
Ab by activating NF-B after having promoted serine
phosphorylation of I-Ba. Using a reporter gene lumi-
nescent assay, we demonstrated that TGFb1 activated
NF-B (Figure 5A), more than doubling its activity in
cultured neurons. Moreover, the reporter gene assay
revealed a modest but significant decrease in NF-B
activity produced by Ab, which significantly failed to
prevent TGFb1-induced activation of NF-B. In accor-
dance with this observation, we found that TGFb1
increased neuronal Hes1 mRNA expression, while Ab
induced a significant reduction in Hes1 expression (Fig-
ure 5B). Indeed, exposure to TGFb1 partially restored
the low levels of Hes1 expression induced by Ab. These
results demonstrate that TGFb1 opposes the effects of
Ab on NF-B activation and Hes1 expression.
Based on the above findings, we examined the anti-amy-
loid effects of TGFb1 on neuronal morphology, connectiv-
ity and survival (Figure 5C-F). TGFb1 blocked the effects
of Ab on dendrite length and number (Figure 5C, D), and
it prevented the Ab-induced decrease in the number of
GABAergic terminals (Figure 5C, E). Finally, administra-
tion of TGFb1 to cultured neurons protected about 50%
of neurons from Ab neurotoxicity Figure 5F). These
Figure 4 Transforming growth factor b1 (TGFb1) controls dendrite morphology and neuronal connectivity via I-Ba and Hes1.
Hippocampal neurons (7 days in vitro (DIV), 40,000 cells/cm2) were treated with TGFb1 (10 ng/ml) before they were co-transfected with pEGFP
and plasmids overexpressing either myc-tagged Hes6 (A) or mutant forms of FLAG-tagged I-Ba (B) for 16 h. The neurons were then processed
for immunocytochemistry using anti-EGFP and anti-myc/anti-FLAG antibodies. (A) Overexpression of Hes6, a known inhibitor of Hes1, abrogated
the effects of TGFb1 on dendritic length (left panel) and on the number of primary dendrites (middle panel). Hes6 overexpression also prevented
the TGFb1-induced increase in the number of GABAergic terminals (right panel). (B) Transfection of I-Ba S32-36A (a mutation that affects serine
phosphorylation of the inhibitor) prevented the TGFb1-induced increase in dendritic length (left panel) and attenuated the formation of vesicular
inhibitory amino acid transporter (VIAAT)-positive clusters (right panel). The I-Ba Y42F mutation that affects the tyrosine phosphorylation of the
inhibitor had no effect on TGFb1 activity. *P < 0.05, **P < 0.01, and ***P < 0.001.
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Figure 5 Tranforming growth factor b1 (TGFb1) activates nuclear factor kappa-B (NF-B) and induces Hes1 expression, controlling
dendrite morphology and GABAergic connectivity, and conferring cultured neurons with resistance to amyloid beta (Ab) neurotoxicity.
(A) Dual-luciferase NF-B reporter gene assay. After transfecting NF-B-luc and RL-TK-luc, 7 days in vitro (DIV) hippocampal neurons were incubated
for 16 h and the neurons were then exposed to Ab (5 μM) with TGFb1 (10 ng/ml) added to the medium 1 h later. The neurons were analyzed after
a further 4 h incubation and the data represent the means of six experiments. (B) Cultured neurons (7 DIV, 300,000 cells) were treated with Ab
(5 μM) and then TGFb1 (10 ng/ml) 1 h later, and the cells incubated for a further 16 h. After lysing the cells, Hes1 expression was quantified by real
time PCR (the means of 10 determinations are shown). (C-E) Hippocampal neurons (7 DIV, 40,000 cells/cm2) were transfected with enhanced green
fluorescent protein (EGFP) and treated with Ab (5 μM) and/or TGFb1 (10 ng/ml). After 16 h, immunostaining for EGFP and vesicular inhibitory
amino acid transporter (VIAAT) was performed as described in Materials and methods. (C) Representative micrographs of cultured neurons under
different conditions (the lower panels show the boxed regions at higher magnification). (D) Morphometric analysis of Ab- and TGFb1-treated
neurons. TGFb1 increased the length (left panel) and decreased the number (right panel) of primary dendrites, thereby counteracting the effects of
Ab. (E) Quantification of GABAergic clusters. TGFb1 increased the number of GABAergic terminals in cultured neurons and overrode the decrease in
GABAergic terminals induced by Ab. (F) Hippocampal neurons (7 DIV, 30,000 cells/cm2) were treated with Ab (5 μM) and/or TGFb1 (10 ng/ml) for
90 h and the number of intact nuclei were counted after 4’,6-diamidino-2-phenylindole (DAPI) staining. TGFb1 prevented Ab-induced death of a
portion of cultured hippocampal neurons. *P < 0.05, **P < 0.01, and ***P < 0.001.
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results emphasize the potential of TGFb1 as a neuropro-
tective agent and reveal, at least in part, the molecular
basis of this neuroprotective activity.
Discussion
The effect of NF-B activity on neuron survival
Transcription factors, including NF-B, are implicated in
experience-based synaptic regulation, and mouse models
involving altered NF-B activity have revealed the impor-
tance of the various forms of this transcription factor in
learning and memory (reviewed in [26]). NF-B may
influence neuronal plasticity at multiple levels as it med-
iates neurite outgrowth [27] and participates in the devel-
opment of dendritic spines [28]. NF-B also plays an
important role in the dendritic development of Purkinje
cells, since when it is inhibited with a lysyl oxidase pep-
tide, serious deficits in dendritic arborisation are pro-
voked [29]. Here, we show that p65/RelA transfection
induces significant changes in the morphology of the
dendrites emitted by cultured hippocampal neurons.
These alterations were similar to those previously
described for NGF, the effects of which are partially
mediated by NF-B [13]. Overexpression of p65/RelA
induces an increase in dendritic length and a decrease in
dendrite number within 16 h. Perhaps more importantly,
p65/RelA overexpression counteracts the effects of Ab
on dendrite morphology, decreasing dendrite length and
increasing the number of primary dendrites. This finding
provides an important indication of the anti-amyloid
effects of p65/RelA overexpression.
NF-B exerts neuroprotective effects against some neu-
rotoxic agents [30,31], including Ab [32], and total abroga-
tion of NF-B activation by pharmacological agents was
followed by hippocampal neuron death (Figure S2A in
Additional file 2). However, with the exception of bcl-XL
induction [33] and the suppression of apoptotic proteins
such as Bax and Bim [34], the mechanisms underlying
NF-B-induced neuroprotection remain elusive. In neu-
rons, NF-B is required to maintain high GluR1 levels and
neuronal hyperexcitability following the induction of long-
term potentiation (LTP) [35]. However, increases in
NF-B activity in response to enhanced excitatory trans-
mission may accelerate the onset of the cognitive defect in
a mouse model of Alzheimer’s disease [36]. The present
results show that p65/RelA promotes GABAergic connec-
tivity in cultured hippocampal neurons, as revealed by the
substantial increases in terminals containing VIAAT. We
previously reported a substantial loss of VIAAT-labeled
terminals shortly after Ab administration in cultured hip-
pocampal neurons [12] These effects were fully prevented
by overexpressing p65/RelA, which may explain the basis
underlying the anti-amyloid activity of NF-B.
Together with inhibitors of NF-B kinases, NF-B reg-
ulates many physiological responses, and activation of
IKK in neurons should induce similar cellular changes to
those elicited by p65/RelA overexpression. The canonical
pathway of NF-B activation involves I-Ba phosphory-
lation via activation of the IKK complex (reviewed in
[37]). Transfection of hippocampal neurons with a plas-
mid expressing IKKb promoted dendritic growth while
decreasing the number of primary dendrites. Further-
more, IKKb transfection prevented Ab from altering den-
dritic patterning. Most importantly, IKKb overexpression
protected a significant number of neurons from the dele-
terious effects of Ab. Thus, canonical activation of NF-
B conferred amyloid resistance to cultured hippocampal
neurons.
The role of Hes1 in anti-amyloid neuroprotection
Hes1 is an important target of IKKb/NF-B in terms of
its influence on neuronal morphology and survival. Acti-
vation of NF-B by NGF increases Hes1 expression,
whereas specific inhibition of this nuclear factor abro-
gates the activity of the neurotrophin [12,13] and it even-
tually caused cell death (Figure S2A in Additional file 2).
We found that overexpression of either IKKb or p65/
RelA induces an increase in Hes1 expression in trans-
fected hippocampal neurons. To further demonstrate
that both the morphological and anti-amyloid effects of
IKKb and p65/RelA depend upon Hes1 expression, we
transfected neurons with a vector that drives the overex-
pression of this gene. Hes1 overexpression induced the
same morphological changes as seen following IKKb or
p65/RelA overexpression, including a large increase in
GABAergic connectivity. As expected, Hes1 overexpres-
sion counteracted the effects of Ab on cell morphology
and GABAergic terminals, and strikingly, overexpression
of Hes1 also rescued 50% of neurons from Ab-induced
death. Conversely, inhibition of Hes1 activity by overex-
pression of Hes6 induced cell death (Figure S2B in Addi-
tional file 2). Together, these findings indicate that
correct expression of Hes1 confers anti-amyloid resis-
tance to cultured hippocampal neurons, strongly suggest-
ing that strategies to increase Hes1 expression and
activity may protect neurons from Ab toxicity.
TGFb1 provides an alternative means of promoting Hes1
expression and inducing anti-amyloid activity
TGFb1 has long been recognized as a neuroprotective
agent (for a review see [38]) and indeed, neurodegeneration
[39,40] and Ab deposition [41] are enhanced in TGFb1-
deficient mice. Furthermore, components of the hippocam-
pal TGFb pathway are altered in schizophrenia and
psychiatric disorders [42]. Several TGFb signalling path-
ways have been elucidated [43] and the canonical pathway
involves the activation and nuclear localization of the
Smad complex, where it modulates target gene transcrip-
tion. However, our data suggest that the neuroprotective
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activity of TGFb1 is not mediated by this canonical path-
way but rather, by NF-B/Hes1. Administration of TGFb1
to cultured neurons alters dendritic patterning and
GABAergic connectivity in a manner consistent with Hes1
overexpression. Moreover, transfection with Hes6, an inhi-
bitor of Hes1 transcriptional activity [19,20,25], abrogated
all the effects of TGFb1 on neuronal morphology and con-
nectivity. Although Hes1 upregulation by TGFb1 has been
reported previously in fibroblasts [44], this is the first time
the regulation of this bHLH gene by TGFb1 has been
described in hippocampal neurons.
Further assays of neuronal morphology and connectivity
revealed the involvement of I-Ba in TGFb1 signalling.
Transfection with a serine mutant form of I-Ba abolishes
the effects of TGFb1 on both dendritic shape and on the
number of GABAergic terminals. However, a tyrosine
mutant form of I-Ba had no effect on TGFb1 activity,
indicating that serine phosphorylation of I-Ba preceded
NF-B activation in this pathway. Direct biochemical mea-
surements revealed that treatment of cultured neurons
with TGFb1 promoted NF-B activation and Hes1 expres-
sion. The activation of NF-B by TGFb1 has been
reported previously in cultured hippocampal neurons
from rat embryos [22]. However, we also observed that
TGFb1 reversed the loss in NF-B activity and Hes1
expression induced by Ab. Indeed, TGFb1 also prevented
the formation of VIAAT-positive clusters in response to
Ab, and it prevented Ab from altering dendrite patterning.
Most importantly, TGFb1 rescued a significant portion of
neurons from Ab-induced death. These findings confirm
the neuroprotective capacity of this cytokine and the
underlying role of NF-B activation and Hes1 expression.
We showed previously that the action of Ab is exerted
in part by inhibiting early steps in the NGF signalling
pathway, including the deactivation of RhoA and the acti-
vation of PTP1B, both events that are needed for NF-B
activation and to promote Hes1 expression [15]. Accord-
ingly, TGFb1 can circumvent such effects by activating
NF-B through an alternative mechanism that involves
the serine phosphorylation of I-B, as shown here. How-
ever, when NF-B activation was pharmacologically
impaired by SN-50 or when Hes1 activity was blocked by
Hes6 overexpression, TGFb1 activity was abrogated
(Figure S2A and S2B in Additional file 2). Together, these
results suggest that on the one hand, NF-B activation
and Hes1 activity are needed for cell survival, and on the
other, that TGFb1 exert its anti-amyloid activity by poten-
tiating NF-B and Hes1 activities.
Modulation of GABAergic input in neuroprotection
Growth factors may control synaptic development and
transmission in quantitative terms. Brain-derived neuro-
trophic factor (BDNF) upregulates glutamatergic input
and downregulates the number of GABAergic synaptic
terminals [45], while insulin promotes the postsynaptic
accumulation of GABAA receptors by increasing Akt-
mediated phosphorylation of b subunits (reviewed in
[46]). NGF also increases the expression of GABAergic
terminals in cultured hippocampal neurons, an effect
mediated by altering Hes1 expression [13]. Via the cano-
nical pathway involving Smad4, TGFb1 is a critical fac-
tor in use-dependent modulation of GABAA-mediated
synaptic transmission and dendrite homeostasis [47].
In all experimental paradigms assayed here, including
the transfection of cultured neurons with IKKb, I-Ba or
p65/RelA and the exposure of cultured neurons to
TGFb1, VIAAT immunocytochemistry indicated that
there was a large increase in the expression of GABAer-
gic terminals. These experimental approaches also
consistently prevented Ab from affecting GABAergic
terminals, since exposure to Ab decreases the number of
GABAergic connections after 16 h and kills cells after
90 h. Thus, there is compelling evidence that Hes1 is an
important element in the maintenance of GABAergic
connectivity, although the mechanisms underlying this
phenomenon remain unknown. The increase in GABAer-
gic input promoted by NF-B/Hes1 may provide a nega-
tive feedback in the control of excitatory activity and
consequently, protect neurons from excitotoxicity. The
increase in inhibitory activity induced by NF-B
Figure 6 Transforming growth factor b1 (TGFb1), nerve growth
factor (NGF) and amyloid beta (Ab)-induced signaling in
hippocampal neurons. Diagram outlining the signal transduction
pathways downstream of TGFb1 that promote Hes1 expression and
neuronal survival. How NGF is impaired by Ab is also illustrated. In
contrast to NGF, the activation of NF-B and the increased
expression of Hes1 induced by TGFb1 are not inhibited by Ab.
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activation or TGFb1 administration may account for the
neuroprotective effects observed. Indeed, TGFb1 plays an
important role in the excitatory/inhibitory balance of hip-
pocampal transmission [47].
Conclusions
The findings presented here support the notion that neu-
rons can be protected from the noxious effects of Ab by
modulating inhibitory transmission. Moreover, strategies
that mildly activate NF-B and/or that enhance Hes1
expression could provide beneficial neuroprotection. Sig-
nificantly, TGFb1 signalling counteracts the inhibitory
effect of Ab on NGF signalling (summarized in Figure 6),
possibly supplementing the attenuated activity of NGF in
Alzheimer’s disease and representing a potential target for
the development of anti-amyloid therapies.
Additional material
Additional file 1: Figure showing molecular characterization and
neurotoxic properties of the amyloid b (Ab) preparations used in
this study. (A) The preparations of Ab were characterized in western
blots probed with an anti-Ab antibody following Bis-Tris PAGE separation
(see Methods). Lane (1) shows that the stock preparation mostly
contained monomeric and dimeric species, with smaller quantities of
trimeric and tetrameric forms. In lanes 2 to 5, Ab was added to 35 mm
culture dishes that containing one glass polylysine coated 2 × 2 cm
coverslip and 2 mL of medium at the concentrations indicated. After a
three-day incubation at 37°C, aliquots of the medium were taken and
resolved by electrophoresis (supernatant, snt, lanes 2 and 3).
Simultaneously, the glass coverslips were washed with LDS sample buffer
and the material released was also separated in the same gels
(immobilized on glass, imm, lanes 4 and 5). Note that the incubation of
amyloid favoured the formation of higher molecular weight forms,
although most species were small oligomers and the larger aggregates,
including fibrils, only represented a small fraction of the amyloid. (B)
Hippocampal neurons (7 days in vitro (DIV) and 30,000 cells/cm2) were
treated with Ab as indicated. After 90 h, the cells were fixed and stained
with 4’,6-diamidino-2-phenylindole (DAPI) to asses the integrity of their
nuclei. Note that Ab (5 μM) produced a high rate of cell death, which
justified the use of this concentration in further experiments. VF,
microscope view field.
Additional file 2: Figure showing the nuclear factor kappa B (NF-B)
pathway and Hes1 activity are needed for the survival of neurons,
while transforming growth factor b1 (TGFb1) is unable to rescue
cells from death. E17 hippocampal neurons were plated at a density of
30,000 cells/cm2 and cultured for 7 days in vitro (DIV). Neurons were (A)
treated for 24 h with SN-50 (5 μM) or with its control peptide in the
presence or absence of TGFb1 (10 ng/ml). (B) Neurons were co-
transfected with enhanced green fluorescent protein (EGFP) and a myc-
tagged Hes6 vector for 48 h in the presence or absence of TGFb1. The
cells were fixed and labeled with anti-EGFP and anti-myc antibodies,
while the integrity of their nuclei was assessed by 4’,6-diamidino-2-
phenylindole (DAPI) staining. Note that the obliteration of either NF-B
activation or Hes1 activity was followed by neuron death. The addition of
TGFb1 did not reverse these effects.
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